Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
PMID 9469685
It belongs to a separate receptor family (amylin/calcitonin) and adds a complementary signaling axis to the GLP-1 conversation rather than competing within it
If you feel great and your energy levels are steady, youve likely found your "sweet spot." If you begin to feel bloated or "off," simply scale back
Higher dose exploration (4.5mg trials) Rationale for testing 4.5mg: Investigate maximum tolerable dose Determine if higher = better weight loss Establish safety ceiling Results at 4.5mg weekly: Weight loss: ~12% (vs 10% at 2.4mg) Incremental benefit: Only 2% additional loss Side effects: Significantly worse nausea/vomiting Dropout rate: Higher than 2.4mg Clinical verdict: 4.5mg not recommended for routine use Risk-benefit ratio unfavorable 2.4mg remains optimal Some individuals may tolerate 3.0mg as compromise CagriSema combination dosing trials REDEFINE-1 protocol: Semaglutide: 2.4mg weekly (standard titration over 16 weeks) Cagrilintide: 2.4mg weekly (12-week titration) Both given as separate injections Started simultaneously from week 1 Semaglutide escalation (standard): Weeks 1-4: 0.25mg Weeks 5-8: 0.5mg Weeks 9-12: 1.0mg Weeks 13-16: 1.7mg Week 17+: 2.4mg Cagrilintide escalation (when combined): Weeks 1-4: 0.6mg Weeks 5-8: 1.2mg Weeks 9-12: 1.8mg Week 13+: 2.4mg Results: 15.6% average weight loss (68 weeks) Superior to either alone Side effects manageable with slow titration Combination well-tolerated See our cagrilintide and semaglutide combination guide and semaglutide dosage calculator
Furthermore, research published in the journal Obesity Science & Practice highlighted the benefits of semaglutide for long-term weight maintenance, demonstrating sustained reductions in body weight and improvements in obesity-related comorbidities over time
Mutations in this pathway lead to uncontrolled growth and proliferation
